Targeted Nanoparticle Drug Delivery System for the Enhancement of Cancer Immunotherapy
- 1 September 2019
- journal article
- review article
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 15 (9), 1839-1866
- https://doi.org/10.1166/jbn.2019.2827
Abstract
Immunotherapy is one of the most potent options for cancer treatment, with numerous breakthroughs in this field, bringing us closer to the realization of cancer eradication. However, the intrinsic limits of immunotherapy, such as its low responsive rate, narrow therapeutic window and systemic toxicity, have hindered its clinical application and thus prompted the development of nanotechnology-assisted modality for more effective and safer cancer immunotherapy. By locally increasing the drug concentration and limiting drug exposure to normal tissues, nanocarriers significantly potentiate the effects of immunotherapy while reducing side effects. Additionally, nanoparticle-based drug delivery systems allow different therapeutic strategies as a complement to conventional immunotherapeutic modalities, providing numerous novel and effective approaches for combinational cancer therapy. In this review, we first briefly introduce the five main classes of immunotherapy, and then we extensively covered some advanced biomaterials and novel strategies of nanotechnology intervention and detailed how these approaches function to enhance immunotherapeutic and combinational combination therapeutic efficacy.Keywords
This publication has 273 references indexed in Scilit:
- ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophagesCell Research, 2013
- The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STINGCell Reports, 2013
- Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapyNature Materials, 2012
- Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticlesBiomaterials, 2012
- Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapyBiomaterials, 2011
- Cytokines and the inception of CD8 T cell responsesTrends in Immunology, 2011
- Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer ModelThe American Journal of Pathology, 2011
- Therapeutic cell engineering with surface-conjugated synthetic nanoparticlesNature Medicine, 2010
- Progress and prospects: immune responses to viral vectorsGene Therapy, 2009
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007